CWA Asset Management Group LLC Buys 3,563 Shares of Boston Scientific Corporation (NYSE:BSX)

CWA Asset Management Group LLC increased its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 43.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,844 shares of the medical equipment provider's stock after buying an additional 3,563 shares during the quarter. CWA Asset Management Group LLC's holdings in Boston Scientific were worth $1,195,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Wolf Group Capital Advisors acquired a new stake in Boston Scientific in the first quarter valued at $2,144,000. Clarius Group LLC raised its holdings in shares of Boston Scientific by 34.8% in the 1st quarter. Clarius Group LLC now owns 11,493 shares of the medical equipment provider's stock valued at $1,159,000 after purchasing an additional 2,968 shares during the period. CENTRAL TRUST Co raised its holdings in shares of Boston Scientific by 108.7% in the 1st quarter. CENTRAL TRUST Co now owns 11,472 shares of the medical equipment provider's stock valued at $1,157,000 after purchasing an additional 5,976 shares during the period. PKO Investment Management Joint Stock Co lifted its stake in Boston Scientific by 30.0% in the 1st quarter. PKO Investment Management Joint Stock Co now owns 13,000 shares of the medical equipment provider's stock valued at $1,311,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Rakuten Securities Inc. grew its holdings in Boston Scientific by 122.8% during the first quarter. Rakuten Securities Inc. now owns 998 shares of the medical equipment provider's stock worth $101,000 after purchasing an additional 550 shares during the period. 89.07% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,572 shares of the company's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $104.54, for a total transaction of $477,956.88. Following the completion of the sale, the executive vice president now directly owns 18,705 shares in the company, valued at $1,955,420.70. This represents a 19.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the firm's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total value of $5,799,551.36. Following the completion of the sale, the executive vice president now directly owns 178,342 shares in the company, valued at approximately $18,347,824.96. This represents a 24.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 411,970 shares of company stock worth $42,406,693 over the last ninety days. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Trading Down 0.4%

Shares of BSX stock opened at $101.36 on Friday. The stock has a market cap of $149.96 billion, a P/E ratio of 73.99, a price-to-earnings-growth ratio of 2.62 and a beta of 0.68. Boston Scientific Corporation has a 1 year low of $71.88 and a 1 year high of $107.17. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47. The stock has a 50 day simple moving average of $101.62 and a 200 day simple moving average of $98.98.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. The firm had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The company's revenue was up 20.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.56 EPS. On average, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on BSX shares. Citigroup restated a "buy" rating and issued a $125.00 price objective (up previously from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Evercore ISI boosted their target price on Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Erste Group Bank upgraded Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Barclays raised their price target on Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Finally, Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Twenty-two analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Boston Scientific has a consensus rating of "Buy" and a consensus target price of $116.09.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.